These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1638524)

  • 1. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.
    Kwak LW; Campbell MJ; Levy R
    Cancer Res; 1992 Aug; 52(15):4117-20. PubMed ID: 1638524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease.
    Bryson JS; Jennings CD; Lowery DM; Carlson SL; Pflugh DL; Caywood BE; Kaplan AM
    Bone Marrow Transplant; 1999 Feb; 23(4):363-72. PubMed ID: 10100580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
    Weiss L; Reich S; Slavin S
    Bone Marrow Transplant; 1995 Sep; 16(3):457-61. PubMed ID: 8535320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
    De Ruysscher D; Sobis H; Vandeputte M; Waer M
    J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation.
    Kedar E; Tsuberi BZ; Landesberg A; Anafi M; Leshem B; Gillis S; Urdal DL; Slavin S
    Bone Marrow Transplant; 1988 Jul; 3(4):297-314. PubMed ID: 3048495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice.
    Agah R; Malloy B; Kerner M; Girgis E; Bean P; Twomey P; Mazumder A
    Cancer Res; 1989 Nov; 49(21):5959-63. PubMed ID: 2790810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
    Ho SP; Stebler B; Ershler WB
    Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery.
    Tiberghien P; Longo DL; Wine JW; Alvord WG; Reynolds CW
    Blood; 1990 Oct; 76(7):1419-30. PubMed ID: 2207317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine cytomegalovirus infection can enhance hybrid resistance through modulation of host natural killer activity.
    Muluk SC; Hakim FT; Shearer GM
    J Immunol; 1990 Aug; 145(4):1113-9. PubMed ID: 2166108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy.
    Charak BS; Brynes RK; Katsuda S; Groshen S; Chen SC; Mazumder A
    Cancer Res; 1991 Apr; 51(8):2015-20. PubMed ID: 2009520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M; Bukhari Z; Sachs DH
    Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival.
    Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S
    Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
    Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.